Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is a biotechnology company headquartered in Carlsbad, California, dedicated to discovering and developing RNA-targeted therapeutics. The company's mission is to deliver life-transforming therapies to people with serious diseases by pioneering RNA-targeted therapeutics, aiming to translate the promise of RNA-based medicines into life-changing treatments for patients.

Ionis specializes in antisense therapy, RNA interference, and CRISPR therapeutics, focusing on a broad range of diseases including neurological, cardiometabolic, and rare genetic disorders. Key marketed products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin-mediated amyloidosis, Waylivra (volanesorsen) for familial chylomicronemia syndrome, Qalsody (tofersen) for a genetic form of ALS, TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome, and DAWNZERA (donidalorsen) for hereditary angioedema.

In recent news, Ionis Pharmaceuticals reported strong first-quarter 2026 financial results, surpassing Wall Street expectations and leading to an increase in its full-year 2026 revenue guidance. The company's independent product launches, particularly TRYNGOLZA and DAWNZERA, have significantly contributed to revenue growth. Ionis continues to advance its pipeline, with the U.S. FDA accepting New Drug Applications for donidalorsen for prophylactic treatment of HAE, olezarsen for Priority Review in severe hypertriglyceridemia, and zilganersen for Alexander disease, positioning the company for further independent launches. Brett P. Monia serves as the Chief Executive Officer.

Latest updates

Ionis Boosts Guidance on Strong Commercial Performance, Pipeline Momentum

Event summary

  • Ionis reported Q1 2026 revenue of $246 million, an 87% increase year-over-year.
  • The company increased its full-year 2026 revenue guidance from $800-825 million to $875-900 million.
  • Olezarsen peak net sales guidance was raised to >$3 billion, reflecting increased confidence in the severe hypertriglyceridemia market.
  • Key upcoming events include EASL presentation of bepirovirsen data next month and the HORIZON and CARDIO-TTRansform trial results later in 2026.

The big picture

Ionis's strong Q1 performance and revised guidance signal a shift towards greater revenue generation from independent launches, reducing reliance on royalty income. The company's focus on rare disease therapies positions it to capitalize on unmet medical needs, but success hinges on navigating regulatory hurdles and demonstrating clinical efficacy in pivotal trials. The increased olezarsen peak sales guidance reflects a growing confidence in the market opportunity, but also introduces execution risk associated with commercialization and competition.

What we're watching

Execution Risk
The success of olezarsen and zilganersen launches, along with the anticipated regulatory approvals, will be critical to Ionis achieving its revised financial guidance and long-term growth targets.
Clinical Data
The results from the bepirovirsen, HORIZON, and CARDIO-TTRansform trials will significantly impact Ionis’ valuation and future development plans, particularly regarding partnered programs.
Market Dynamics
How the competitive landscape in the hypertriglyceridemia space evolves will influence olezarsen’s market share and Ionis’ ability to sustain its increased revenue projections.

GSK's Hepatitis B Candidate Secures FDA Priority Review, Breakthrough Designation

Event summary

  • The U.S. FDA has accepted a New Drug Application (NDA) for bepirovirsen, a GSK-developed antisense oligonucleotide (ASO) for chronic hepatitis B (CHB), for Priority Review.
  • Bepirovirsen has also been granted Breakthrough Therapy Designation by the FDA, setting a PDUFA target action date of October 26, 2026.
  • Phase 3 trials (B-Well 1 and B-Well 2) demonstrated statistically significant and clinically meaningful functional cure rates with bepirovirsen plus standard of care.
  • Ionis Pharmaceuticals licensed bepirovirsen to GSK in 2019, receiving upfront and milestone payments, with tiered royalties on net sales.
  • Regulatory reviews are also underway with the EMA, NMPA, and MHLW, with similar designations secured in China and Japan.

The big picture

Chronic hepatitis B affects over 250 million people globally, representing a significant unmet medical need. Current treatments offer limited functional cure rates, creating an opportunity for bepirovirsen to disrupt the market. GSK's investment in Ionis's ASO technology underscores the growing interest in RNA-targeted therapies for chronic diseases, but the high price point of such therapies could limit accessibility.

What we're watching

Regulatory Risk
The October 2026 PDUFA date introduces regulatory risk; a rejection or significant delay would impact both GSK and Ionis's revenue projections and stock performance.
Market Adoption
The success of bepirovirsen will depend on its ability to displace existing nucleoside analogues and convince physicians to adopt a novel treatment approach, potentially facing reimbursement hurdles.
Clinical Durability
Long-term data on the durability of the functional cure achieved with bepirovirsen will be critical to assess its true value proposition and potential for sustained market adoption.

Ionis Zilganersen Data Bolsters Rare Disease Pipeline, FDA Decision Looms

Event summary

  • Ionis presented additional positive data from a pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD) at the AAN 2026 Annual Meeting.
  • The study met its primary endpoint in patients ≥5 years of age, demonstrating statistically significant stabilization of gait speed.
  • Results from the GMFM-88 showed potential improvement in gross motor function in children aged 2-4 years.
  • Zilganersen reduced plasma GFAP levels by 33.6% at Week 61, consistent with its mechanism of action.
  • The FDA is expected to make a decision on zilganersen's approval by September 22, 2026, under Priority Review.

The big picture

Ionis's zilganersen program represents a significant effort to address a previously unmet medical need in a rare disease space, which often commands premium pricing. The positive data reinforces the potential of RNA-targeted therapies for neurological disorders, but the small patient population and high development costs create inherent risks. The FDA decision will be a key inflection point for Ionis, impacting its credibility in the rare disease space and influencing its broader pipeline strategy.

What we're watching

Regulatory Risk
The FDA’s September action date will be critical; a rejection or significant delay could substantially impact Ionis’s valuation and future pipeline prospects.
Commercialization
Given the rarity of AxD (estimated 1 in 1-3 million), Ionis will need to demonstrate a clear commercialization strategy and pricing model to justify the investment and ensure patient access.
Pipeline Impact
The success or failure of zilganersen will likely influence investor sentiment and development decisions for Ionis’s other RNA-targeted therapies in neurology and beyond.

Ionis Zilganersen NDA Acceptance Signals Potential Breakthrough in Rare Disease Treatment

Event summary

  • Ionis Pharmaceuticals received Priority Review designation from the FDA for zilganersen, a treatment for Alexander disease (AxD).
  • The FDA has set a PDUFA target action date of September 22, 2026.
  • Clinical trial data demonstrated statistically significant stabilization in gait speed (33.3%, p=0.0412) with zilganersen compared to control.
  • The pivotal study enrolled 54 participants across 13 sites in eight countries, with a majority being children.
  • Zilganersen, if approved, would be the first treatment for AxD, marking Ionis’ first independent commercial launch in neurology.

The big picture

The acceptance of the zilganersen NDA underscores the growing focus on rare disease treatments, a segment often characterized by high unmet need and premium pricing. Ionis’ entry into independent neurology commercialization represents a strategic shift, aiming to diversify revenue streams beyond its established RNA therapeutics portfolio. The success of zilganersen will be a crucial test of Ionis’ ability to navigate the complexities of launching and scaling a new therapy for a small patient population.

What we're watching

Regulatory Risk
The September 2026 PDUFA date presents a near-term catalyst, but approval is not guaranteed and hinges on FDA assessment of clinical data and safety profile.
Commercial Execution
Ionis’ ability to successfully launch and commercialize zilganersen independently in neurology will be a key indicator of its broader strategic ambitions in the therapeutic area.
Competitive Landscape
While currently no approved treatments exist, the emergence of alternative therapies or competing approaches for AxD could impact zilganersen’s market share and pricing power.

Ionis Board Shakeup Signals Shift Towards Growth, Regulatory Expertise

Event summary

  • Lynne Parshall and Joseph Wender are retiring from Ionis’ Board of Directors at the end of their terms, effective June 4, 2026.
  • Peter Reikes is rejoining the Ionis Board of Directors, also effective June 4, 2026.
  • Lynne Parshall served in various executive roles at Ionis from 1991-2017, including COO and CFO.
  • Joseph Wender, previously Lead Independent Director, served as a senior consultant to Goldman Sachs since 2008.
  • Peter Reikes recently served as a senior strategy advisor with ARPA-H and previously as a senior advisor to the FDA.

The big picture

The board changes at Ionis reflect a broader trend of biotech companies seeking directors with deep regulatory and financial expertise to guide them through increasingly complex development and commercialization landscapes. The addition of Peter Reikes, with his experience advising both ARPA-H and the FDA, suggests Ionis is prioritizing navigating the evolving regulatory environment and accelerating pipeline advancement. The departure of long-standing directors also indicates a potential shift in strategic focus, possibly towards more aggressive growth initiatives.

What we're watching

Governance Dynamics
The departure of long-tenured directors Parshall and Wender signals a potential shift in board priorities and oversight, which could impact Ionis’ strategic direction.
Regulatory Headwinds
Reikes’ prior experience with ARPA-H and the FDA suggests a heightened focus on navigating regulatory pathways and potentially influencing policy, which could accelerate or decelerate pipeline development.
Execution Risk
The company’s stated focus on “rapid growth and pipeline progress” will require effective integration of Reikes’ expertise and execution against ambitious goals, potentially exposing vulnerabilities if not managed effectively.

Ionis DAWNZERA Data Bolsters HAE Treatment Position

Event summary

  • Ionis Pharmaceuticals will present eight poster presentations at the 2026 AAAAI Annual Meeting focused on DAWNZERA (donidalorsen) for hereditary angioedema (HAE).
  • The presentations include analyses from Phase 3 OASIS-HAE and OASISplus studies, focusing on patient switching, adherence, adolescent efficacy, and real-world disease control.
  • DAWNZERA is the first and only RNA-targeted medicine approved for HAE prophylaxis in the U.S. and EU, targeting plasma prekallikrein (PKK).
  • The company estimates HAE affects over 20,000 people in the U.S. and Europe.

The big picture

Ionis’s DAWNZERA represents a significant advancement in treating HAE, a rare disease with substantial unmet need. The company’s focus on RNA-targeted therapies positions it within a growing segment of precision medicine, but success hinges on demonstrating sustained efficacy and managing potential safety concerns. The data presented at AAAAI will be a key indicator of DAWNZERA’s long-term commercial viability and Ionis’s broader strategic direction within the specialty pharmaceutical market.

What we're watching

Adoption Rate
The presentation of real-world adherence data will be crucial in assessing DAWNZERA’s ability to displace existing prophylactic treatments and achieve broader market penetration within the HAE patient population.
Safety Profile
Continued monitoring of hypersensitivity reactions, as highlighted in the safety information, will be vital to maintaining regulatory approval and patient confidence in DAWNZERA’s long-term safety.
Pipeline Expansion
Ionis’s focus on RNA-targeted medicines suggests a potential for expanding its HAE pipeline beyond DAWNZERA, which could intensify competition and necessitate strategic differentiation.

Ionis Olezarsen Priority Review Offers Hope for Untreated Hypertriglyceridemia

Event summary

  • The FDA has granted Priority Review to Ionis’ supplemental New Drug Application (sNDA) for olezarsen, a treatment for severe hypertriglyceridemia (sHTG).
  • The FDA’s action date is set for June 30, 2026.
  • Phase 3 CORE and CORE2 trials demonstrated a 72% reduction in triglycerides and an 85% reduction in acute pancreatitis events.
  • Olezarsen targets apoC-III, a protein regulating triglyceride metabolism, and is already approved for familial chylomicronemia syndrome (FCS).

The big picture

Severe hypertriglyceridemia affects approximately 3 million people in the U.S., with a significant unmet need given the limitations of current therapies. Ionis’ olezarsen represents a potential breakthrough in addressing this condition, but its success will depend on navigating regulatory hurdles and demonstrating sustained efficacy and safety in a real-world setting. The Priority Review designation accelerates the timeline, but the June 2026 action date remains a critical milestone for the company.

What we're watching

Regulatory Risk
The approval timeline hinges on the FDA’s assessment of the Phase 3 data; a potential delay or rejection would significantly impact Ionis’ valuation.
Market Adoption
The success of olezarsen will depend on physician and patient adoption, which could be limited by the drug's delivery method (subcutaneous injection) and potential cost.
Competitive Landscape
While olezarsen aims to be a first-in-class treatment, the emergence of alternative therapies or novel approaches to managing sHTG could erode its market share.

Ionis Revenue Surges, Pipeline Data Drives 2026 Launch Expectations

Event summary

  • Ionis Pharmaceuticals reported 2025 revenue of $944 million, a 49% increase year-over-year.
  • The company received $280 million upfront payment from Ono Pharmaceutical for the global license of sapablursen.
  • Ionis expects to launch olezarsen for severe hypertriglyceridemia and zilganersen for Alexander disease in 2026.
  • Positive Phase 3 data for bepirovirsen in chronic hepatitis B was reported, with further cardiovascular outcome trials anticipated mid-2026 and late 2026.

The big picture

Ionis's strong 2025 performance, driven by commercial launches and pipeline advancements, positions the company as a key player in the RNA therapeutics space. The company's focus on independent launches, coupled with partnered pipeline programs, represents a strategic shift towards broader patient populations and diversified revenue streams. However, the company's ambitious 2026 launch schedule and reliance on positive clinical trial data introduce significant execution and regulatory risks that investors will closely monitor.

What we're watching

Execution Risk
The success of Ionis’s 2026 launch cadence for olezarsen and zilganersen will be critical to sustaining the current valuation, and any delays could significantly impact investor sentiment.
Regulatory Headwinds
The anticipated regulatory decisions for bepirovirsen and pelacarsen will heavily influence Ionis’s future revenue projections and partnership negotiations, potentially exposing the company to unexpected delays or rejections.
Financial Discipline
Ionis’s ability to achieve cash flow breakeven in 2028, as guided, will depend on effectively managing increased operating expenses associated with commercialization and pipeline advancement, requiring tight cost controls.

Ionis Schedules Q4 2025 Earnings Webcast

Event summary

  • Ionis Pharmaceuticals will host a live webcast on February 25, 2026, at 11:30 AM Eastern Time.
  • The webcast will cover fourth quarter and full year 2025 financial results.
  • A replay of the webcast will be available at https://ir.ionis.com/events-and-presentations/upcoming-events.
  • D. Wade Walke is listed as the Investor Contact for Ionis.

The big picture

Ionis, a long-standing pioneer in RNA-targeted medicines, faces the challenge of translating its technological lead into sustained commercial success. The company's focus on neurology and cardiometabolic diseases represents a significant market opportunity, but also exposes it to intense competition and regulatory scrutiny. The upcoming webcast will provide insight into whether Ionis can deliver on its promises and maintain its competitive edge.

What we're watching

Pipeline Progress
The company's commentary on key programs will reveal the trajectory of its pipeline, particularly given its focus on neurology and cardiometabolic disease, which face increasing competition.
Financial Health
The webcast will need to demonstrate sustainable revenue growth to justify Ionis's valuation, especially considering the capital-intensive nature of RNA therapy development.
Competitive Landscape
The discussion around innovation in RNA therapies and gene editing will likely highlight how Ionis intends to differentiate itself from competitors and maintain its pioneering position.

Ionis DAWNZERA EU Approval Triggers $15M Milestone, Royalties

Event summary

  • Ionis Pharmaceuticals’ DAWNZERA (donidalorsen) received EU approval for HAE prophylaxis in adults and adolescents (12+).
  • The approval is based on positive Phase 3 OASIS-HAE and OASISplus study data, demonstrating a 94% mean monthly attack rate reduction at one year.
  • DAWNZERA is administered via subcutaneous autoinjector every 4-8 weeks.
  • Ionis is eligible for a $15 million milestone payment and tiered royalties (up to 30%) on net product sales.
  • The drug was previously approved by the U.S. FDA in August 2025.

The big picture

The approval of DAWNZERA represents a significant win for Ionis, validating its RNA-targeting technology and expanding its presence in the rare disease market. HAE affects approximately 1 in 50,000 people globally, creating a niche but potentially lucrative market. The partnership with Otsuka provides Ionis with a well-established commercial infrastructure for European distribution, but also means Ionis’s revenue is dependent on Otsuka’s execution.

What we're watching

Commercialization
The speed of DAWNZERA’s rollout across EU markets will be critical, given the drug’s self-administered nature and the need for patient education and access programs.
Competitive Landscape
While currently the only RNA-targeted therapy for HAE, the emergence of alternative prophylactic treatments could erode DAWNZERA’s market share over time.
Royalty Impact
Ionis’s royalty revenue stream will be directly tied to Otsuka’s sales performance, making the partnership’s commercial execution a key factor in Ionis’s financial outlook.
CID: 3866